Jefferies Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM): "We like RYTM into the next 6 months"
Tweet Send to a Friend
Jefferies analyst Dennis Ding reiterated a Buy rating and $125.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM)The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
